Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25521373 | 0.71 | AGBL2 (0.41) | PTGDR2PTGDRAKR1C3AKR1C2LMNA | |
| SCHEMBL27735040 | 0.70 | KDM4E (0.37) | KDM4ELMNA | |
| SCHEMBL7167362 | 0.68 | SLC22A12 (0.42) | KDM4ELMNA | |
| SCHEMBL28153560 | 0.67 | KDM4E (0.50) | KDM4ECYP1A2CYP3A4CYP2C19 | |
| SCHEMBL28189506 | 0.67 | AGBL2 (0.50) | PTGDR2PTGDRAKR1C3AKR1C2KDM4E | |
| SCHEMBL8366327 | 0.65 | PTGDR2 (0.54) | PTGDR2PTGDRAKR1C3AKR1C2KDM4E | |
| SCHEMBL1004061 | 0.64 | MAPT (0.47) | PTGDR2LMNACYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL27146172 | 0.64 | ALDH1A1 (0.55) | KDM4ELMNACYP2C19 | |
| SCHEMBL22066831 | 0.63 | KDM4E (0.50) | PTGDR2PTGDRKDM4ECYP1A2CYP3A4 | |
| SCHEMBL2142648 | 0.63 | CYP1A2 (0.45) | PTGDR2AKR1C3AKR1C2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910357-B1 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LTD (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-20090163534-A1 | Indolizine Derivatives | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-1910357-A2 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2006136859-A2 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163534-A1 | Indolizine Derivatives | HRH4, HRH2, NR1H2 | PTGDR2 363/4885PTGDR 270/4885AKR1C3 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.